Université Paris-Saclay
6
2
3
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 85/100
16.7%
1 terminated/withdrawn out of 6 trials
0.0%
-86.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
Testing of a New Rapid Antigen Test for Plague in Ituri, Democratic Republic of the Congo.
Role: collaborator
Ex-vivo Evaluation of the Effect of 2 Probiotic Solutions (Lactibiane ATB and Lactibiane Enfant) and 5 Classes of Drugs on the Intestinal Microbiota
Role: collaborator
Rapid Recognition of Corticosteroid Resistant or Sensitive Sepsis
Role: collaborator
Evolution of Oropharyngeal and Rectal Microbiota After Severe Traumatic Brain Injury
Role: collaborator
Spatial Cognition Assessment in Virtual Reality
Role: collaborator
Impact of a Stress Management Training Course
Role: lead
All 6 trials loaded